In their discussion, the authors emphasize that because their study focused on patients with no history of gout, it will be important to repeat the analysis for patients with a higher baseline risk of gout to better understand whether the magnitude of potential benefit can be generalized to the larger population.
You Might Also Like
Also By This Author
Lara C. Pullen, PhD, is a medical writer based in the Chicago area.
- Fralick M, Chen SK, Patorno E, et al. Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study. Ann Intern Med. 2020 Jan 14. [Epub ahead of print]